Rocket Pharmaceuticals, Inc. - Common Stock (RCKT)
3.1400
+0.00 (0.00%)
NASDAQ · Last Trade: Jul 28th, 5:56 AM EDT
Detailed Quote
Previous Close
3.140
Open
-
Bid
3.140
Ask
3.300
Day's Range
N/A - N/A
52 Week Range
2.190 - 25.40
Volume
11
Market Cap
206.73M
PE Ratio (TTM)
-1.194
EPS (TTM)
-2.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,607,261
Chart
About Rocket Pharmaceuticals, Inc. - Common Stock (RCKT)
Rocket Pharmaceuticals Inc is a biotechnology company focused on developing innovative gene therapies to treat rare and devastating diseases. Its mission revolves around leveraging advanced genetic science and technology to create transformative therapies that can address the underlying causes of genetic disorders. The company primarily targets conditions that currently lack effective treatment options, with the aim of providing significant clinical benefits and improving the quality of life for patients. By utilizing cutting-edge research and collaborating with leading experts in the field, Rocket Pharmaceuticals strives to bring groundbreaking solutions to the forefront of healthcare. Read More
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
NEW YORK - July 25, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) of a class action securities lawsuit.
NEW YORK - July 24, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) of a class action securities lawsuit.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strategic corporate reorganization and pipeline prioritization aimed at maximizing near-term value, extending operational runway into the second quarter of 2027, and positioning the company for sustained long-term growth.
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK - July 23, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
NEW YORK - July 22, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
NEW YORK - July 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
NEW YORK - July 18, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK - July 17, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
PHILADELPHIA, July 17, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC, a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket Pharmaceuticals” or the “Company”) for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses.
